ScienceDaily (Oct. 23, 2012) Research out of Roswell Park Cancer Institute (RPCI) supports the adoption of a new biomarker to measure the aggressiveness of primary prostate tumors. A team of investigators from three institutions, led by Shahriar Koochekpour, MD, PhD, Associate Professor of Cancer Genetics, Urology and Oncology in RPCI’s Department of Cancer Genetics, has for the first time produced data showing that levels of serum glutamate, a naturally occurring nonessential amino acid that plays a key role in cancer metabolism, are increased in patients with primary and metastatic prostate cancer
ScienceDaily (Oct. 17, 2012) Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL).
ScienceDaily (Oct. 16, 2012) A common birth control device is effective in treating early-stage endometrial cancer in morbidly obese and high-risk surgery patients, said Georgia Health Sciences University Cancer Center researchers, and could lead to a cost-effective treatment for all women with this cancer type. Endometrial cancer, which starts in the lining of the uterus, is the third most common gynecologic cancer, striking more than 47,000 American women every year, particularly the obese.
ScienceDaily (Oct. 10, 2012) Researchers at NYU School of Medicine have discovered the protein product of a little-known gene may one day prove useful in identifying and monitoring the development of mesothelioma in early stages, when aggressive treatment can have an impact on the progression of disease and patient prognosis
ScienceDaily (Oct. 10, 2012) Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October issue of The Lancet Oncology . This is the first study to demonstrate how prognostic markers may be useful in a clinical setting.
ScienceDaily (Oct. 9, 2012) Some animal models developed by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Catalan Institute of Oncology (ICO) has served to validate the effectiveness of a new drug against ovarian cancer resistant to cisplatin. The multidisciplinary work, done in collaboration with the biopharmaceutical company Pharmamar, was published in the journal Clinical Cancer Research.
ScienceDaily (Oct. 7, 2012) A new approach to lung scanning could improve the diagnosis and treatment of a lung disease that affects approximately 24 million Americans and is the country’s third-highest cause of death. In a new paper published online in Nature Medicine , a team from the University of Michigan Medical School reports on a technique called parametric response mapping, or PRM.
ScienceDaily (Sep. 28, 2012) Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to a study published September 29 by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare. TGen researchers tracked several years of tumor evolution in a 47-year-old male patient with maxillary sinus carcinoma (MSC), a rare cancer of the sinus cavities beneath the cheeks that often requires surgical removal that is disfiguring.